Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Lenvatinib + TACE in Advanced HCC
NCT07150377Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Shandong First Medical University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07150377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150377.